SG3 Management’s Cartesian Therapeutics RNAC Stock Holding History

SG3 Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-833	Closed	-$113K	–	1283
2021 Q1	$113K	Buy	+833	New	+$103K	﹤0.01%	1038

Other funds holding RNAC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SG3 Management's RNAC Position: Q2 2021 in Review

SG3 Management sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 833 shares — an estimated $113K sold.

SG3 Management first reported a position in RNAC in Q1 2021 and held it in 1 quarter. The position peaked at $113K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

SG3 Management reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 833 Cartesian Therapeutics shares in Q2 2021, an estimated $113K.
SG3 Management first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 1 quarter.
SG3 Management's Cartesian Therapeutics position peaked at $113K in Q1 2021.
101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.